LPC

Lion Point Capital Portfolio holdings

AUM $19.3M
1-Year Est. Return 110.67%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+110.67%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$19.3M
AUM Growth
+$1.72M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
42
New
Increased
Reduced
Closed

Top Buys

1
+$1.35M
2
+$601K
3
+$590K
4
QURE icon
uniQure
QURE
+$567K
5
JANX icon
Janux Therapeutics
JANX
+$447K

Top Sells

1
+$1.14M
2
+$912K
3
+$909K
4
INSM icon
Insmed
INSM
+$900K
5
ARQT icon
Arcutis Biotherapeutics
ARQT
+$769K

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
QURE icon
26
uniQure
QURE
$654M
$352K 1.82%
+14,700
PCRX icon
27
Pacira BioSciences
PCRX
$901M
$349K 1.81%
+13,500
VTRS icon
28
Viatris
VTRS
$18.1B
$345K 1.78%
+27,700
AZTA icon
29
Azenta
AZTA
$1.24B
$323K 1.67%
+9,700
RCKT icon
30
Rocket Pharmaceuticals
RCKT
$542M
$302K 1.56%
86,000
JANX icon
31
Janux Therapeutics
JANX
$819M
$262K 1.36%
+19,000
EWTX icon
32
Edgewise Therapeutics
EWTX
$3.14B
$226K 1.17%
+9,100
INVA icon
33
Innoviva
INVA
$1.72B
$164K 0.85%
+8,200
ARQT icon
34
Arcutis Biotherapeutics
ARQT
$3.3B
$152K 0.79%
5,250
-30,050
IPHA
35
Innate Pharma
IPHA
$161M
$142K 0.73%
+81,151
NERV icon
36
Minerva Neurosciences
NERV
$286M
$141K 0.73%
+35,000
GHRS icon
37
GH Research
GHRS
$921M
$130K 0.67%
+10,200
SPRB
38
Spruce Biosciences, Inc. Common Stock
SPRB
$58.8M
$87.1K 0.45%
1,000
MRSN
39
DELISTED
Mersana Therapeutics
MRSN
$2.89K 0.02%
100
-25,660
AVDL
40
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-59,700
INSM icon
41
Insmed
INSM
$31.8B
– –
-6,250
KNSA icon
42
Kiniksa Pharmaceuticals
KNSA
$3.37B
– –
-23,400
1
2